Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles For Members Only RA Capital Management, Janus Henderson, Balyasny Back Reverse Merger of Biotech Company Stephen Taub Overseas Stocks Drive Double-Digit Returns for State Plans Like Louisiana and New York James Comtois Podcast- Comprehensive, Not Commoditized: The Key to Traditional Middle Market Underwriting Sponsored by Fidelity Investments